Changeflow GovPing Healthcare & Life Sciences Condensed Pyrazole Derivatives as Inhibitors of...
Routine Rule Added Final

Condensed Pyrazole Derivatives as Inhibitors of SARM1

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted patent US12606558B2 to Disarm Therapeutics, Inc. covering condensed pyrazole derivatives useful as SARM1 inhibitors for treating and preventing axonal degeneration. The patent, granted April 21, 2026, contains 10 claims and names six inventors including Jonathan Bentley Jr. and Robert Owen Hughes.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Grants - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 190 changes logged to date.

What changed

The USPTO granted patent US12606558B2 to Disarm Therapeutics, Inc. covering compounds of formula (I) useful for inhibiting SARM1 and treating or preventing axonal degeneration. The patent contains 10 claims and is classified under CPC codes A61P 25/28 (nervous system disorders) and A61P 25/02 (neuronal disorders).

For biotechnology and pharmaceutical companies developing SARM1-targeted therapeutics for neurological conditions, this patent establishes intellectual property protection for pyrazole-based SARM1 inhibitors. Parties pursuing similar compounds or axonal degeneration treatments should review Freedom to Operate positions and consider licensing discussions with the patent holder.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Condensed pyrazole derivatives as inhibitors of SARM1

Grant US12606558B2 Kind: B2 Apr 21, 2026

Assignee

Disarm Therapeutics, Inc.

Inventors

Jonathan Bentley, Jr., Shelley Anne Parrott, Andrew Simon Brearley, Todd Bosanac, Robert Owen Hughes, Rajesh Devraj

Abstract

The present disclosure provides compounds of formula (I) and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

CPC Classifications

A61P 25/28 A61P 25/02 C07D 471/04 C07D 498/04

Filing Date

2021-04-07

Application No.

17995049

Claims

10

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606558B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Clinical investigators
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Drug compound protection Biotech IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!